Form 4: TScan Therapeutics Director Keith Woods Awarded Options

Director Keith Woods has been granted 67,000 stock options in TScan Therapeutics as part of a standard equity compensation arrangement.

Summary

• Keith Woods, a director at TScan Therapeutics, was granted 67,000 stock options on May 20, 2026.
• The options have an exercise price of $0.9946 per share.
• The grant is scheduled to vest in full on the earlier of May 20, 2027, or the date of the next annual meeting of stockholders.
• The options are set to expire on May 20, 2036.
• Following this transaction, the reporting person holds a total of 67,000 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative event that confirms standard corporate governance and director incentive alignment.

Positives

• Aligns the interests of the director with those of the shareholders through equity-based compensation.
• The exercise price of $0.9946 provides a baseline for potential future value creation.
• Vesting is tied to continued service, ensuring director retention for at least one year.

Negatives

• The exercise of these options will result in a dilution of existing shares by 67,000 units.
• The grant represents a potential future cash outflow for the company if settled in a manner other than standard issuance, though typical for director compensation.

Risks

• The value of the options is entirely dependent on the market price of TCRX stock exceeding the $0.9946 exercise price.
• Vesting is subject to the director's continued service; a departure before May 2027 would result in forfeiture.

Future Outlook

The grant indicates a standard continuation of the company's director compensation program, suggesting stability in the board's composition through the 2027 annual meeting.

Management Comments

• The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of May 20, 2027 and the next annual meeting of the Issuer's stockholders.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is a standard practice in the biotechnology sector to preserve cash while incentivizing long-term strategic oversight.

Comparison to Industry Standards

• The grant size of 67,000 options is consistent with mid-to-small cap biotech firms like Atara Biotherapeutics or TCR2 Therapeutics.
• The one-year cliff vesting schedule is a standard benchmark for non-employee director equity awards in the NASDAQ Biotechnology Index.

Corporate Governance

Related Party Transactions

• Grant of 67,000 stock options to Director Keith Woods as part of his compensation for service on the Board of Directors.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.
• The director is incentivized to increase company value over the next decade.

Next Steps

• Full vesting of the options on May 20, 2027, or the next annual meeting.
• Potential exercise of options by the director any time before the 2036 expiration date once vested.

Key Dates

Recommendation

This is a routine Form 4 filing for director compensation and does not provide new material information regarding the company's clinical progress or financial stability that would warrant a change in investment thesis.

Keywords

TScan Therapeutics, TCRX, Stock Options, Insider Trading, Director Compensation, Keith Woods, Biotechnology, Equity Grant